These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28922168)

  • 1. Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson's Disease.
    Santiago JA; Potashkin JA
    J Parkinsons Dis; 2017; 7(4):653-660. PubMed ID: 28922168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    JAMA Neurol; 2017 Aug; 74(8):933-940. PubMed ID: 28595287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    Neurology; 2014 Nov; 83(19):1739-46. PubMed ID: 25298306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is normosmic Parkinson disease a unique clinical phenotype?
    Lee DH; Oh JS; Ham JH; Lee JJ; Lee I; Lee PH; Kim JS; Sohn YH
    Neurology; 2015 Oct; 85(15):1270-5. PubMed ID: 26354986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease.
    Ponsen MM; Stoffers D; Wolters ECh; Booij J; Berendse HW
    J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):396-9. PubMed ID: 19965851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma apolipoprotein A1 as a biomarker for Parkinson disease.
    Qiang JK; Wong YC; Siderowf A; Hurtig HI; Xie SX; Lee VM; Trojanowski JQ; Yearout D; B Leverenz J; Montine TJ; Stern M; Mendick S; Jennings D; Zabetian C; Marek K; Chen-Plotkin AS
    Ann Neurol; 2013 Jul; 74(1):119-27. PubMed ID: 23447138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiopathic hyposmia as a preclinical sign of Parkinson's disease.
    Ponsen MM; Stoffers D; Booij J; van Eck-Smit BL; Wolters ECh; Berendse HW
    Ann Neurol; 2004 Aug; 56(2):173-81. PubMed ID: 15293269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
    Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
    J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
    Santiago JA; Potashkin JA
    PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell.
    Berendse HW; Booij J; Francot CM; Bergmans PL; Hijman R; Stoof JC; Wolters EC
    Ann Neurol; 2001 Jul; 50(1):34-41. PubMed ID: 11456307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis.
    Posavi M; Diaz-Ortiz M; Liu B; Swanson CR; Skrinak RT; Hernandez-Con P; Amado DA; Fullard M; Rick J; Siderowf A; Weintraub D; McCluskey L; Trojanowski JQ; Dewey RB; Huang X; Chen-Plotkin AS
    PLoS Med; 2019 Oct; 16(10):e1002931. PubMed ID: 31603904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging.
    Berendse HW; Ponsen MM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S26-30. PubMed ID: 20083001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease.
    Berendse HW; Roos DS; Raijmakers P; Doty RL
    J Neurol Sci; 2011 Nov; 310(1-2):21-4. PubMed ID: 21705022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective clinical and DaT-SPECT imaging in premotor
    Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
    Neurology; 2017 Aug; 89(5):439-444. PubMed ID: 28679601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olfactory Dysfunction Predicts Disease Progression in Parkinson's Disease: A Longitudinal Study.
    He R; Zhao Y; He Y; Zhou Y; Yang J; Zhou X; Zhu L; Zhou X; Liu Z; Xu Q; Sun Q; Tan J; Yan X; Tang B; Guo J
    Front Neurosci; 2020; 14():569777. PubMed ID: 33381006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dopamine transporter SPECT in patients with Parkinson's disease].
    Hamano T; Tsuchida T; Hirayama M; Fujiyama J; Mutoh T; Yonekura Y; Kuriyama M
    Kaku Igaku; 2000 Mar; 37(2):125-9. PubMed ID: 10783572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
    Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
    Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease.
    Bohnen NI; Gedela S; Kuwabara H; Constantine GM; Mathis CA; Studenski SA; Moore RY
    J Neurol; 2007 Jan; 254(1):84-90. PubMed ID: 17508142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.